India is witnessing a sharp rise in infectious diseases, with one in nine tests coming positive for dengue and influenza A, ...

Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...

Current treatments for herpes simplex virus 1 (HSV-1) mainly target the viral DNA polymerase, but resistance is becoming an increasing problem. By understanding how HSV-1 initiates replication, ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), announced that Nanoviricides CEO Dr Anil Diwan joined ...

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the ...

This landmark manuscript comprehensively examines the roles of nine structural proteins in herpes simplex virus 1 (HSV-1) assembly and nuclear egress. By integrating cryo-light microscopy and soft ...

Patients with HSV-1 who used antiherpetics were less likely to develop Alzheimer disease than those who did not. HealthDay News — Herpes simplex virus type 1 (HSV-1) is associated with an increased ...

Adults aged 50 years and older with a history of herpes simplex virus type 1 diagnosis were up to 1.8 times more likely to have Alzheimer disease, although the risk was lowered by use of antiherpetics ...

Herpes simplex virus type 1 (HSV-1) is associated with an increased risk for Alzheimer disease (AD) based on real-world data from the United States. HealthDay News — Herpes simplex virus type 1 (HSV-1 ...

A large study suggests that symptomatic infection with herpes simplex virus 1 (HSV-1)—best known for causing cold sores—may significantly raise the risk of developing Alzheimer’s disease. Researchers ...